JNJ

226.12

+0.1%↑

UNH

366.23

-0.28%↓

TMO

464.26

-0.74%↓

ISRG

453.69

-0.41%↓

ABT

86.9

-2.39%↓

JNJ

226.12

+0.1%↑

UNH

366.23

-0.28%↓

TMO

464.26

-0.74%↓

ISRG

453.69

-0.41%↓

ABT

86.9

-2.39%↓

JNJ

226.12

+0.1%↑

UNH

366.23

-0.28%↓

TMO

464.26

-0.74%↓

ISRG

453.69

-0.41%↓

ABT

86.9

-2.39%↓

JNJ

226.12

+0.1%↑

UNH

366.23

-0.28%↓

TMO

464.26

-0.74%↓

ISRG

453.69

-0.41%↓

ABT

86.9

-2.39%↓

JNJ

226.12

+0.1%↑

UNH

366.23

-0.28%↓

TMO

464.26

-0.74%↓

ISRG

453.69

-0.41%↓

ABT

86.9

-2.39%↓

Home・Stock List・Ardelyx Inc

Search

Ardelyx Inc

Open

SectorHealthcare

6.88 8.69

Overview

Share price change

24h

Current

Min

6.82

Max

7.04

Key metrics
By Trading Economics
Income	562K -407K
Sales	15M 125M
EPS	-0.002
Profit margin	-0.325
Employees	489
EBITDA	4.5M 10M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+141.28% upside

Market Stats
By TradingEconomics
Market Cap	-200M 1.5B
Previous open	-1.81
Previous close	6.88

News Sentiment

By Acuity

55%

45%

292 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

3.62 / 3.95 Support & Resistance

Ardelyx Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 May 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 May 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 May 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 May 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 May 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 May 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 May 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 May 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 May 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 May 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 May 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 May 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 May 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 May 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 May 2026, 22:37 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 May 2026, 22:26 UTC

Earnings

Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 May 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 May 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 May 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 May 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 May 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 May 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 May 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 May 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 May 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 May 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 May 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Comparison

Price change

Ardelyx Inc Forecast

Price Target

By TipRanks

141.28% upside

12 Months Forecast

Average 16.6 USD 141.28%

High 19 USD

Low 13 USD

Based on 5 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Based on 5 analysts giving stock ratings to Ardelyx Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.62 / 3.95Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

292 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Other stocks from the sector

JNJ

Johnson and Johnson

226.12

UNH

UnitedHealth Group Inc

366.23

TMO

Thermo Fisher Scientific Inc

464.26

ISRG

Intuitive Surgical Inc

453.69

ABT

Abbott Laboratories

86.9

Live chat